SRPT - Sarepta raised to Outperform at Mizuho on strong results
2025-11-05 13:10:19 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
- FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
- Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Sarepta plunges after late-stage Duchenne trial failure
- Elanco Animal Health set to join S&P MidCap 400, Sarepta to join S&P SmallCap 600